Study summary
Under-the-skin efgartigimod did not beat placebo in chronic ITP
13.7%sustained platelet response, vs 16.2% with placebo
What was tested
Subcutaneous efgartigimod, an FcRn blocker that lowers antibody levels, against placebo in adults with primary ITP.
What they found
- Sustained response was 13.7% vs 16.2% with placebo (not significant).
- The earlier intravenous trial (ADVANCE IV) had been positive; a new IV trial is under way.
What it means
Leaves the role of FcRn blockers in ITP unsettled.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.